Safety, Pharmacokinetics, and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analog (177)Lu-DOTA-EB-TATE in Patients with Advanced Metastatic Neuroendocrine Tumors

What Was Tested

Researchers studied Octreotide and Somatostatin in this clinical trial, phase i publication.

The aim of this first-in-humans study is to explore the safety and dosimetry of a long-acting radiolabeled somatostatin analog, 177Lu-1, 4, 7, 10-tetra-azacyclododecane-1, 4, 7, 10-tetraacetic acid-Evans blue-octreotate (177Lu-DOTA-EB-TATE).

Why It Was Studied

Radiolabeled somatostatin analog therapy has become an established treatment method for patients with well to moderately differentiated unresectable or metastatic neuroendocrine tumors (NETs).

The most frequently used somatostatin analogs in clinical practice are octreotide and octreotate.

Who Took Part

According to the abstract, 6 men were involved.

The age groups tagged for this paper are adults and middle-aged adults, both men and women.

Methods: Eight patients (6 men and 2 women; age range, 27-61 y) with advanced metastatic NETs were recruited.

What Was Measured

Topics PubMed links to this paper include Coordination Complexes, Evans Blue, Kidney, Lutetium, Neuroendocrine Tumors, Octreotide and Organometallic Compounds.

The authors tagged it with the keywords TATE, neuroendocrine tumor (NET), peptide receptor radionuclide therapy (PRRT) and somatostatin receptor (SSTR).

What This Means in Plain Language

This is a clinical trial, phase i of Octreotide and Somatostatin in 6 men.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 2018 (Journal of nuclear medicine : official publication, Society of Nuclear Medicine), a journal based in United States.

More context: the Octreotide compound page and the Somatostatin compound page, all human trials.